Cost effectiveness of cancer drugs: comparative analysis of the United States and England

5 November 2020 - England's National Institute for Health and Care Excellence and the US’ Institute for Clinical and Economic Review ...

Read more →

Future unrelated medical costs need to be considered in cost effectiveness analysis

5 March 2019 - New medical technologies that prolong life result in additional health care use in life years gained. Some ...

Read more →

What is the evidence from past NICE single-technology appraisals regarding company submissions with base-case incremental cost-effectiveness ratios of less than £10,000/QALY?

22 March 2018 - NICE has recently proposed that company submissions with a base-case incremental cost-effectiveness ratio of less than ...

Read more →

Unrelated future costs and unrelated future benefits: reflections on NICE Guide to the Methods of Technology Appraisal

3 July 2016 - This editorial considers the vexing issue of ‘unrelated future costs’ (for example, the costs of caring ...

Read more →